Would that option include the limited partnership of his family? I guess anything can be written into a CEO contract, but sounds unlikely to me.
You don't pay top rate on all the money. It's scaled. I checked the tax tables.He nets about 65% on federal, or $520K. Penn state tax probably sucks too.
This is truly awesome news. As much as called the bottom. Must have mortgaged his eternity for this. For once, I can't wait for the open tomorrow. Oh, and let's not forget Steve's 10K shares. That certainly puts us over the top!
Sadly, this point only adds to AF's credibility with the street. I wanted to see the miserable person miserably wrong.
I re-read geezerbela's previous posts. Many are very informative. In this case the thought of re-doing P2 is unpalatable to many, including myself, however, I hope geezer keeps posting. Overall, he has made strong contributions to the dialogue. Like an old-time circuit preacher, self-appointed "monitors" will always flame those who offer an opinion out of their orthodoxy.
A mercy killing. That would be great, given a total portfolio price. Go for it, Merck, Roche, et al.
Well, it was In FF At the time of my post. down 12% about that time , now down "only" 9.5%. Let's call 12% "almost FF." I overstated, you understated. This for the record.
You made a good call on your sale. I expected optimism from Dr. Kim, leading to an up day, but no such luck. Sal's right. Time to go clean my basement, organize my CD's. Too early to drink wine.
One hour? Try the trend line since April 1st. $14 to $9. With one brief blip up, then back down. I agree up front, that is not long term, but neither is it short term or inconsequential. Look, nothing goes straight up, but many had hoped for, and been led to believe, that performance would be better. No use for us to continue this banter. I'm sure you expected better too. I like your optimism, but it was just a little too much for me on this day, which feels more like a wake to me.
Oh stop the krap, dman. You aren't the arbiter of who is a true long. People have lost their hard earned money here. Yes, they are moving forward, but they have over-promised and under-delivered. READ the market!
This conference call and INO in 2014. Downward spiral with r/s; downward spiral with release of P2 data; downward spiral with S-3 on day of data release; downward spiral with this cc and lack of an expected partnership. Downward spiral with no mention of INO in the fight with the new diseases cropping up in U.S. Dead money for another year. 2014 has been a serious disappointment. $45,000 equity on 7,500 share (a typical INO position) has disappeared. All the pumping needs to stop until this company delivers SOMETHING. They have spent their goodwill. AF no friend of mine or anyone else on this board, but he has been vindicated more than we have. I will continue to hold and monitor, just wanted to express my extreme disappointment at the weakness of INO, not only for the past year, but for the foreseeable.
I own both. Market prices move on potentials more than actuals. Potential market for MNKD is hugh. Potential market for EDAP with U.S. was hugh, without just "good."
Smugness. The consider anything less than a hundreds of millions of dollars comparison to current medieval treatments such as cryo to be "anecdotal." Common sense observation and rich patient history not allowed at FDA.